Ben George

MEK inhibitor-based therapy in metastatic pancreatic adenocarcinoma with KRAS G12R alteration.

Elizabeth Diane Auckley, Grace W Ying, Stephanie Yohay, Mohammed Aldakkak et autres

725 Background: Pancreatic ductal adenocarcinoma (PDAC) is largely driven by oncogenic alterations in the KRAS , TP53 , CDKN2A/B , and SMAD4 genes. KRAS G12R accounts for nearly 20% of KRAS alterations in PDAC, is biologically unique, and offers the potential for …

us (code pays fourni par la source)

MEK inhibitor-based therapy in metastatic pancreatic adenocarcinoma with KRAS G12D or KRAS G12V alteration.

Stephanie Yohay, Grace W Ying, Elizabeth Diane Auckley, Mohammed Aldakkak et autres

726 Background: Up to 95% of pancreatic ductal adenocarcinomas (PDAC) are driven by oncogenic alterations in the KRAS gene, with KRAS G12D (40%) and KRAS G12V (30%) mutations being the most common. However, in most cases, KRAS alterations are accompanied by alterations …

us (code pays fourni par la source)

AI-Derived Electronic Tumor Marker (e19-9) Can Measure Treatment Response and Outcomes in CA19-9 Non-Producers with Pancreatic Ductal Adenocarcinoma

Anai N. Kothari, Sam Z. Thalji, Mohammed Aldakkak, Gopika SenthilKumar et autres

us (code pays fourni par la source)

Prediction of Severity Levels of Alzheimer's Disease from a Comprehensive MRI Data Analysis: An Explainable Ai Framework for Clinical Insights

Abraham Mullasseril Varghese, Vinu Sherimon, GP Prashanth, Ben George

Zimbabwe (code pays fourni par la source)

Definitive Chemoradiation Associated with Improved Survival Outcomes in Patients with Synchronous Oligometastatic Esophageal Cancer

Thomas Matoska, Anjishnu Banerjee, Aditya Varnam Shreenivas, Lauren Jurkowski et autres

BACKGROUND: The study of oligometastatic esophageal cancer (EC) is relatively new. Preliminary data suggests that more aggressive treatment regimens in select patients may improve survival rates in oligometastatic EC. However, the consensus recommends palliative treatment. We hypothesized that oligometastatic esophageal cancer patients …

us (code pays fourni par la source)

ASO Visual Abstract: CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/ nab-Paclitaxel for Patients with Operable Pancreatic Cancer

Sam Z. Thalji, Mandana Kamgar, Ben George, Mohammed Aldakkak et autres

us (code pays fourni par la source)

Treatment sequencing for patients with localized duodenal and ampullary adenocarcinoma.

Abhishek Janardan, Ben George, Gulrayz Ahmed, Sherin Daniel et autres

783 Background: Duodenal adenocarcinomas (DA) and ampullary adenocarcinoma (AA) are rare, comprising less than 1% of all gastrointestinal cancers. Optimal treatment sequencing strategies for patients with localized DA and AA have not been prospectively validated. We analyzed the clinical outcomes of patients …

us (code pays fourni par la source)

IMMU-13. LARGE SCALE TUMOR MUTATIONAL BURDEN ANALYSIS OF PEDIATRIC TUMORS PROVIDES A DIAGNOSTIC TOOL FOR GERMLINE PREDISPOSITION AND REVEALS NOVEL CANDIDATES FOR IMMUNE CHECKPOINT INHIBITION

Brittany B. Campbell, Paola Angelini, David Fabrizio, Julia Andrea Elvin et autres

BACKGROUND: A significant amount of childhood brain tumors emerge from cancer predisposition syndromes. Although tumor sequencing is common practice, it is currently impossible to infer germline mutations from tumor data. Glioblastoma Multiforme arising in children with Biallelic Mismatch Repair Deficiency Syndrome (bMMRD) …

ca, us, it, se, au (code pays fourni par la source)

p53 Gene and Protein Status: The Role of p53 Alterations in Predicting Outcome in Patients With Bladder Cancer

Ben George, Ram H. Datar, Lin Wu, Jie Cai et autres

PURPOSE: The p53 gene status (mutation) and protein alterations (nuclear accumulation detectable by immunohistochemistry; p53 protein status) are associated with bladder cancer progression. Substantial discordance is documented between the p53 protein and gene status, yet no studies have examined the relationship between …

us (code pays fourni par la source)

COREC: the end of trainee-driven clinical research?

Neelam Patel, Ben George, A Chandratreya, Steve Bollen

Since 1 March 2004 anyone who wishes to set up clinical trials in the United Kingdom has to go through an extensive application process to gain ethical approval. The Central Office for Research Ethics Committees (COREC) was set up by the government …

gb (code pays fourni par la source)

Conflicts of interest among articles published in the Journal of Clinical Oncology

Ben George, S. Simhan, J. A. Lee, Michelle Ann Mathiason et autres

6633 Background: The integrity of scientific and clinical research is dependent on the avoidance of conflicts of interest (COI). Hence, the American Society of Clinical Oncology (ASCO) has implemented a COI policy pertaining to articles published in the Journal of Clinical Oncology …

us (code pays fourni par la source)

Papillary glioneuronal tumor: not always a benign tumor?

Christine Adam, M. Polivka, Alexandre C. Carpentier, Ben George et autres

Papillary glioneuronal tumor (PGNT) is a variant of ganglioglioma, characterized by a pseudopapillary structure with a single pseudostratified layer of small, cuboidal, GFAP-positive cells around hyalinized blood vessels. To date, less than 30 cases have been described with a usually benign course. …

fr (code pays fourni par la source)